Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

What Is Driving Fresh Interest In CONMED Stock Today

CONMED (CNMD) is back in focus as investors assess the adoption of its AirSeal, Buffalo Filter, and BioBrace platforms, along with tariff headwinds and slower AirSeal growth, in the context of the company's broader earnings profile.

See our latest analysis for CONMED.

CONMED's share price has moved to US$49.25 after a strong 30 day share price return of 14% and a 90 day share price return of 36.12%. However, the 1 year total shareholder return is still down 7.4%. This suggests momentum has picked up recently while longer term holders remain under water.

If the recent move in CONMED has you looking beyond a single stock, this is a good moment to broaden your search and uncover 40 healthcare AI stocks.

CONMED has a broad surgical portfolio and fresh share price momentum after recent gains. The real test now is whether that improving sentiment lines up with what you are actually paying for the business.

Most Popular Narrative: 8.2% Overvalued

On the most followed valuation narrative, CONMED's fair value sits at $45.50 compared with the last close at $49.25, which puts investors slightly ahead of that reference point and makes the underlying assumptions worth a closer look.

The accelerating adoption of minimally invasive and robotic-assisted surgeries, combined with CONMED's strong positioning via AirSeal and BioBrace (including expanding use cases and positive clinical feedback), is expected to support durable procedure volume growth and increase recurring revenue, contributing to sustained top-line growth.

Read the complete narrative.

Want to see how this growth story is built? The narrative relies on rising procedure volumes, improving margins and a future earnings profile that looks very different to today.

Result: Fair Value of $45.50 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, CONMED still faces pressure from supply chain recovery issues and its reliance on hospital capital budgets, which could challenge the upbeat narrative if conditions tighten.

Find out about the key risks to this CONMED narrative.

Another View On CONMED's Valuation

The first narrative frames CONMED as 8.2% overvalued relative to a fair value of $45.50. Using P/E tells a different story. At 26.1x earnings, CONMED trades below peers at 33x and below a fair ratio of 32.1x, which points to potential upside if sentiment shifts.

Story Continues

For investors who lean more on earnings multiples than cash flow models, that gap suggests the market is pricing in extra execution risk rather than paying up for future growth. The question is whether you think that discount reflects hidden problems or a possible opportunity.

See what the numbers say about this price — find out in our valuation breakdown.NYSE:CNMD P/E Ratio as at Aug 2026

Next Steps

If the mixed signals around CONMED have you unsure, it makes sense to move quickly and look through the numbers yourself. To weigh both the concerns and the potential upsides in one place, review the 3 key rewards and 3 important warning signs.

Looking For More Ideas Beyond CONMED?

If CONMED has sharpened your focus, do not stop here. Use these screens to quickly spot other opportunities that could fit your approach.

Capture potential mispricing by reviewing 53 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their profiles. Strengthen your income watchlist by scanning 10 dividend fortresses that aim to pair higher yields with resilient business models. Prioritise capital preservation by assessing 80 resilient stocks with low risk scores that show lower risk scores while still offering room for returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CNMD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments